Biotech News

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Immatics (IMTX)Immatics2026-05-31 13:00 ESTClinical readout

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a

Open original release

Related news

IMTXImmatics2026-06-01 12:00 EST

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

IMTXImmatics2026-04-21 14:26 EST

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

IMTXImmatics2026-04-17 19:00 EST

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

IMTXImmatics2026-03-05 12:00 EST

Immatics Announces Full Year 2025 Financial Results and Business Update

IMTXImmatics2025-12-11 12:00 EST

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

IMTXImmatics2025-12-05 11:01 EST

Immatics Announces $125 Million Underwritten Offering

IMTXImmatics2025-11-17 12:00 EST

Immatics Announces Third Quarter 2025 Financial Results and Business Update

IMTXImmatics2025-11-12 12:00 EST

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

View all latest news

Immatics

Immatics is an immunotherapy company focused on T-cell receptor science and cancer immunotherapies. The company is building a platform around targeted immune recognition in oncology.

Recent company news

IMTXBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

IMTXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

IMTXMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

IMTXAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

IMTXGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 9.29 USD
Market cap: 1.37B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States